Tivanisiran

Summary

Tivanisiran (CHEMBL3707356) is a phase-3 clinical-stage oligonucleotide; indicated across 2 conditions including dry eye syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Oligonucleotide
• Indications: 2 conditions
• Clinical trials: 5

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3707356
Name	Tivanisiran
Type	Oligonucleotide
Max phase	3

Also known as: SYL 1001, Syl-1001, SYL-1001, SYL1001, Tivanisiran, TIVANISIRAN

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
dry eye syndrome	3	MONDO:0006733	EFO:1000906

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	2
PHASE1/PHASE2	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04819269	PHASE3	COMPLETED	Tivanisiran for Dry Eye in Subjects With Sjögren’s Syndrome
NCT05310422	PHASE3	COMPLETED	Safety Study of Tivanisiran to Treat Dry Eye
NCT01776658	PHASE1/PHASE2	COMPLETED	Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain
NCT02455999	PHASE2	COMPLETED	Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain
NCT01438281	PHASE1	COMPLETED	Study to Evaluate the Ocular Tolerance of SYL1001 in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).